{"created":"2021-03-01T06:16:58.244395+00:00","id":12678,"links":{},"metadata":{"_buckets":{"deposit":"170de003-8eac-4f68-8776-8c22dfdcee31"},"_deposit":{"id":"12678","owners":[],"pid":{"revision_id":0,"type":"depid","value":"12678"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00012678","sets":["453:456","471:537:538:1030"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Multi-institutional Randomized Control Trial on the Efficacy of Adjuvant Chemotherapy Using Gemcitabine : A Preliminary Study"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2005-02","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"94","bibliographicPageStart":"90","bibliographicVolumeNumber":"119","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: We evaluated gemcitabine as postoperative adjuvant chemotherapy for patients with resectable advanced pancreatic cancer. Study design: Multi-institutional randomized control trial for phase IE clinical study. Patients and Methods: Patients who underwent a curative surgery for the pancreatic cancer of Stage n, fll, and F a were enrolled in this study. The chemotherapy group has been received administration of biweekly 1000mg/m2 gemcitabine for 6 months after surgery, while the surgery-alone group has not been received any anticancer drug. The primary end-point was the disease-free survival, over-all survival and feasibility. Results: Twelve patients were enrolled in this trial from 7 institutions from November 2001 to August 2003. The chemotherapy was well tolerated with mild symptomatic and hematologic toxi-cities. The Grade 3 toxicity was observed only in two patients; one was nausea and vomiting requiring dripped infusion and the other was leucocytopenia. However, from the close micro-scopic examination, only 6 patients were eligible. Conclusions: Adjuvant systemic chemotherapy using gemcitabine was feasible with acceptable adverse effects. Further investigation for gemcitabine - based chemotherapy is warranted.","subitem_description_type":"Abstract"}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"黒崎, 功"}],"nameIdentifiers":[{"nameIdentifier":"84402","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"二瓶, 幸栄"}],"nameIdentifiers":[{"nameIdentifier":"84403","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"横山, 直行"}],"nameIdentifiers":[{"nameIdentifier":"84404","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"畠山, 勝義"}],"nameIdentifiers":[{"nameIdentifier":"84405","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"土屋, 嘉昭"}],"nameIdentifiers":[{"nameIdentifier":"84406","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"清水, 武昭"}],"nameIdentifiers":[{"nameIdentifier":"84407","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-07"}],"displaytype":"detail","filename":"KJ00004300071.pdf","filesize":[{"value":"604.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"KJ00004300071.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/12678/files/KJ00004300071.pdf"},"version_id":"760d2ab3-b57b-4d06-9813-42199a526520"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"膵癌","subitem_subject_scheme":"Other"},{"subitem_subject":"gemcitabine","subitem_subject_scheme":"Other"},{"subitem_subject":"無作為化比較試験","subitem_subject_scheme":"Other"},{"subitem_subject":"術後補助療法","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点"},{"subitem_title":"膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","1030"],"pubdate":{"attribute_name":"公開日","attribute_value":"2007-05-10"},"publish_date":"2007-05-10","publish_status":"0","recid":"12678","relation_version_is_last":true,"title":["膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:45:27.444993+00:00"}